STAT3 and glioblastoma: Comparative analyses of the anti-GBM therapeutic effects of garcinol and stattic, a selective inhibitor of STAT3/5A activation and dimerization, revealed that akin to the 25–98% reduction in cell viability of the primary GBM culture cells by 2.5–40 μM static, equimolar garcinol treatment dose-dependently elicited a 13–96.8% reduced viability of the primary GBM culture cells (Figure 6A).